Treatment of a patient with disseminated testicular germ cell tumor associated with terminal chronic kidney disease requiring hemodialysis
A. S. Ablyametova,
A. V. Zorinova,
A. N. Letuchikh,
E. R. Israelyan,
A. S. Tsareva,
A. A. Rumyantsev https://doi.org/10.18027/2224-5057-2024-019
Abstract
There is a cohort of cancer patients with terminal chronic kidney disease (CKD) due to various causes and requiring hemodialysis. Antitumor drug therapy in this concomitant disease is possible, but requires selection of the most optimal modified chemotherapy (CT) regimens to maximize efficacy and minimize treatment toxicity. In this case report we describe our therapeutic approach for a patient on hemodialysis with a metastatic non-seminomatous germ cell tumor (GCT) of the testis of poor prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification. We analyzed the literature datareflecting the use of different drugs and CT regimens used for the treatment of GCT in patients with CKD.
Supporting agencies: The article was prepared without sponsorship
About the Authors
A. S. Ablyametova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Ablyametova Avasherfe Sapuetovna
23 Kashirskoe Shosse, Moscow 115478; 1 Ostrovityanova St., Moscow 117997
Competing Interests:
The authors declare that there are no possible conflicts of interest
A. V. Zorinova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Zorinova Alina Vladimirovna
23 Kashirskoe Shosse, Moscow 115478; 1 Ostrovityanova St., Moscow 117997
Competing Interests:
The authors declare that there are no possible conflicts of interest
A. N. Letuchikh
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Letuchikh Angelina Nikolaevna
23 Kashirskoe Shosse, Moscow 115478; 1 Ostrovityanova St., Moscow 117997
Competing Interests:
The authors declare that there are no possible conflicts of interest
E. R. Israelyan
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Israelyan Edgar Rudikovich
23 Kashirskoe Shosse, Moscow 115478
Competing Interests:
The authors declare that there are no possible conflicts of interest
A. S. Tsareva
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Tsareva Anastasiya Sergeevna
23 Kashirskoe Shosse, Moscow 115478
Competing Interests:
The authors declare that there are no possible conflicts of interest
A. A. Rumyantsev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Rumyantsev Aleksei Aleksandrovich
23 Kashirskoe Shosse, Moscow 115478
Competing Interests:
The authors declare that there are no possible conflicts of interest
References
1. Alifrangis С., Sharma A., Chowdhury S., et al. Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. EurJ Cancer 2022;164:105-113. https://doi.Org/10.1016/j.ejca.2020.08.031
2. Bajorin D.F., Sarosdy M.F., Pfister D.G., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993;ll(4):598-606. https://doi.Org/10.1200/JCO.1993.ll.4.598
3. Horwich A., Sleijfer D.T., Fossa S.D., et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15(5):1844-52. https://doi.org/10.1200/JC0.1997.15.5.1844
4. Feldman D.R., Bosl G.J., Sheinfeld J., et al. Medical treatment of advanced testicular cancer. JAMA 2008;299(6):672-84. https://doi.Org/10.1001/jama.299.6.672. PMID: 18270356
5. Hanna N.H., Einhorn L.H. Testicular cancer-discoveries and updates. N Engl J Med 2014;371(21):2005-16. https://doi.org/10.1056/NEJMral407550. Erratum in: N EnglJ Med 2014;371(24):2342. PMID: 25409373
6. Feldman D.R. State-of-the-Art Management of Germ Cell Tumors. Am Soc Clin Oncol Educ Book 2018;38:319-323. https://doi.org/10.1200/EDBK_201139
7. Gillessen S., Sauve N., Collette L., et al. International Germ Cell Cancer Classification Update Consortium. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol 2021;39(14):1563—1574. https://doi.org/10.1200/JCO.20.03296. Erratum in: J Clin Oncol 2022;40(20):2283. PMID: 33822655
8. Fizazi K., Pagliaro L., Laplanche A., et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumors (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 2014;15:1442-1450. https://doi.org/10.1016/S1470-2045(14)70490-5
9. Janus N., Launay-Vacher V., Yhyss A., et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 2013;24(2):501—507. https://doi.org/10.1093/annonc/mds344
10. Bokemeyer C., Kohrmann O., Tischler J., et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumors. Ann Oncol 1996;7(10):1015—21. https://doi.org/10.1093/oxfordjournals.annonc.a010493
11. Moore K.J., Snow S., Wood L.A. Delivering Chemotherapy to a Metastatic Poor Risk Testicular Cancer Patient on Hemodialysis. Curr Oncol 2022;29(3):1808-1812. https://doi.org/10.3390/curroncol29030148
12. Gorodetsky R., Vexler A., Bar-Khaim Y., et al. Plasma platinum elimination in a hemodialysis patient treated with cisplatin. Ther Drug Monit 1995;17(2):203—6. https://doi.org/10.1097/00007691-199504000-00018
13. Ikeda K., Terashima M., Kawamura H., et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol 1998;28(3):168-75. https://doi.Org/10.1093/jjco/28.3.168
14. Janus N., Thariat J., Boulanger H., et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010;21(7):1395—1403. https://doi.org/10.1093/annonc/mdp598
15. Crooke S.T., Luft F., Broughton A., et al. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer 1977;39(4):1430—4. https://doi.org/10.1002/1097-0142(197704)39:4<1430::aid-cncr2820390412>3.0.co;2-v
16. Latcha S., Maki R.G., Schwartz G.K., et al. Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis. Sarcoma 2009;2009:575629. https://doi.org/10.1155/2009/575629
17. Hirakawa H., Nakashima Ch., Nakamura T., et al. Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report. J Med Case Rep 2017;ll(l):43 https://doi.org/10.1186/sl3256-017-1213-7
18. Froehner M., Passauer J., Schuler U., et al. Successful chemotherapy for advanced nonseminomatous germ-cell tumor in a patient undergoing chronic hemodialysis. J Clin Oncol 2007;25(10):1282-4. https://doi.org/10.1200/JCO.2006.09.9549
19. Tryakin A., Fedyanin M., Bulanov A., et al. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.J Cancer Res Clin Oncol 2018;144(9):1817-1823. https://doi.org/10.1007/s00432-018-2695-4
20. Williams S.D., Birch R., Einhorn L.H., et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N EnglJ Med 1987;316(23):1435-40. https://doi.org/10.1056/NEJM198706043162302
21. Crooke S.T., Luft F., Broughton A., et al. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer 1977;39(4):1430—4. https://doi.org/10.1002/1097-0142(197704)39:4<1430::aid-cncr2820390412>3.0.co;2-v
22. R de Wit., Stoter G., Sleijfer D.T., et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998;78(6):828-32. https://doi.org/10.1038/bjc,1998.587
23. Feldman D., Hu J., Srinivas S., et al. Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate-or poor-risk germ cell tumors (GCT). J Clin Oncol 2018;36(15 suppl):4508-4508. https://doi.org/10.1200/JCO.2018.36.15_suppl.4508
24. Collette L., Sylvester R.J., Stenning S.P., et al. Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 1999;91(10):839-46. https://doi.org/10.1093/jnci/91.10.839
25. Клинические рекомендации. Герминогенные опухоли у мужчин, 2020. Доступно по: https://cr.minzdrav.gov.ru/recomend/584_l
Review
For citations:
Ablyametova A.S., Zorinova A.V., Letuchikh A.N., Israelyan E.R., Tsareva A.S., Rumyantsev A.A. Treatment of a patient with disseminated testicular germ cell tumor associated with terminal chronic kidney disease requiring hemodialysis. Malignant tumours. 2024;14(3):79-85. (In Russ.) https://doi.org/10.18027/2224-5057-2024-019
Views:
149
Email this article 